The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy

Cancer

Volumn 83, Issue 8, 1998, Pages 1529-1539

  Pinder, S E ^a   Murray, S ^b,c,d   Ellis, I O ^a   Trihia, H ^b,m   Elston, C W ^a   Gelber, R D ^b,e   Goldhirsch, A ^b,f   Lindtner, J ^b,g   Cortes Funes H ^b,h   Simoncini, E ^b,i   Byrne, M J ^b,j   Golouh, R ^b,f   Rudenstam, C M ^b,k   Castiglione Gertsch, M ^b,l   Gusterson, B A ^b,m  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b International Breast Cancer Study Group   (Switzerland)

^c IBCSG Statistical Center   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g INSTITUTE OF ONCOLOGY   (Slovenia)

^h Madrid Breast Cancer Group   (Spain)

ⁱ SPEDALI CIVILI   (Italy)

^j SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l IBCSG Coordinating Center   (Switzerland)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

Breast carcinoma; Chemotherapy; Histologic grade; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR DIFFERENTIATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ESTROGEN ANTAGONISTS; FEMALE; FLUOROURACIL; FORECASTING; HUMANS; LYMPH NODES; MASTECTOMY; METHOTREXATE; NEOPLASM INVASIVENESS; POSTMENOPAUSE; PREDNISONE; PREMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TAMOXIFEN;

EID: 15644376845     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1529::AID-CNCR7>3.0.CO;2-V     Document Type: Article

References (22)

1. Johnson AE, Bennett MH, Cox SJ, Cheung CWD, Sales JEL. The management of individual breast cancers. Breast 1995; 4:100-11.
2. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990;26:1035-8.
3. Neville AM, Bettelheim R, Gelber RD, SaveSoderbergh J, Davis BW, Reed R, et al. Factors predicting treatment responsiveness and prognosis in node negative breast cancer. J Clin Oncol 1992;10:696-705.
4. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
5. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987: 300-11.
6. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11: 359-77.
7. National Co-ordinating Committee for Breast Screening Pathology. Pathology reporting in breast cancer screening. 2nd edition. Sheffield: NHSBSP Publications, 1995.
8. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer: let's do it. Am J Clin Pathol 1995;103:123-4.
9. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N EnglJ Med 1989; 320:491-6.
10. Goldhirsch A, Gelber RD, Price KN, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994;343:377-81.
11. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blarney RW, et al. Pathological prognostic factors in breast cancer. IV. Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27: 219-26.
12. Davis BW, Gelber R, Goldhirsch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 1985;16:1212-5.
13. Ellis IO, Galea M, Broughton N, Locker A, Blarney RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type: relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20:479-89.
14. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol 1992;10;1049-56.
15. Landis JR, Koch GG. The measurements of observer agreement for categorical data. Biometrics 1977;33;159-74.
16. Walker KJ, Bouzubar N, Robertson J, Ellis IO, Elston CW, Blarney RW, et al. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res 1988;48: 6517-22.
17. Tubiana M, Koscielny S. Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 1991;18:125-40.
18. Lovekin C, Ellis IO, Locker A, Robertson IFR, Bell J, Nicholson R, et al. c-erb B-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
19. Frierson H Jr., Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-8.
20. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: a reproducibility study. Cancer 1994;73: 2765-70.
21. Robbins P, Pinder S, De Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995; 26: 873-9.
22. Fisher ER, Redmond C, Fisher B, and participating NSABP investigators. Pathologic findings from the National Surgical Adjuvant Breast Project: relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 1983;51:181-91.